Effectiveness of Lanzhou lamb rotavirus vaccine against rotavirus gastroenteritis requiring hospitalization: a

Chuanxi Fu1, Ming Wang, Jianhua Liang

  • 1Guangzhou Centre for Disease Control and Prevention, Guangzhou, China.

Vaccine
|November 21, 2007
PubMed

Insights

The Lanzhou lamb rotavirus (LLR) vaccine showed 73.3% effectiveness against rotavirus gastroenteritis requiring hospitalization in children under 5. One dose was moderately effective, especially in older infants.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Gastroenterology

Background:

  • Rotavirus gastroenteritis is a significant cause of hospitalization in children under 5 years old.
  • Assessing the real-world vaccine effectiveness (VE) of available vaccines is crucial for public health strategies.

Purpose of the Study:

  • To determine the vaccine effectiveness (VE) of the Lanzhou lamb rotavirus (LLR) vaccine.
  • To evaluate LLR vaccine efficacy against rotavirus gastroenteritis necessitating hospitalization in children younger than 5 years.

Main Methods:

  • A case-control study design was employed.
  • Children hospitalized with rotavirus gastroenteritis between 2002 and 2004 were identified as cases.
  • Cases were matched to 838 controls by gender, age, and community; vaccine effectiveness was calculated for one or more LLR vaccine doses.

Main Results:

  • The LLR vaccine demonstrated a VE of 73.3% (95% CI, 61.2-81.6%) for one dose versus zero doses.
  • VE was higher in children aged 12-23 months (80.9%) compared to those aged 2-11 months (60.0%).

Conclusions:

  • A single dose of the Lanzhou lamb rotavirus vaccine is moderately effective in preventing rotavirus gastroenteritis requiring hospitalization.
  • The vaccine's effectiveness is notable, particularly in children aged 12-23 months.